Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.

Also called NCT02926937

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 399 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02926937
  • EudraCT 2016-001799-31
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02926937. Randomized; double masking; primary purpose treatment. Start 2016-11-11 (actual); primary completion 2019-04-22 (actual). Results posted on 2021-06-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sotagliflozin (SAR439954)
Intervention (Drug)
Placebo
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02926937
Content hash
7d30b7d6b6b5aba660a8711e8e3069f1d4825440a38a4300a2b35242ed112572